Prostate Cancer Nexus
The Medthority Prostate Cancer Nexus is committed to uncovering and amplifying the conversations that matter in prostate cancer. Our mission is to educate and improve healthcare delivery, and enhance patient outcomes, by providing clear, concise, and impactful resources for healthcare professionals. We aim to foster a learning environment that is both informative and user-friendly, pinpointing the insights that can empower and enable meaningful change to your practice.
Recently added - over the past 2 weeks - news articles, content from either lz - only 3 tiles
Updated phase III data of an exploratory cohort from the ACCESS-1 trial investigating pozelimab + cemdisiran (poze-cemdi) against ravulizumab, in paroxysmal nocturnal hemoglobinuria.- Regeneron
Roundtable: mCRPC update 2024
Analysis of trials on current and emerging treatments
Expert opinions on mCRPC management
Insights on mCRPC treatments, guideline barriers, patient populations, and trial designs from Professors Axel Merseburger and Neeraj Agarwal.
Latest news
Related Guidelines
1 mins
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.